Nurix Therapeutics Stock Rises on Strong Financial Results and Analyst Upgrade

Nurix Therapeutics shares are trading higher after the company reported robust Q2 financial results with significant milestone achievements and Jefferies initiated coverage with a 'Buy' rating and a $41 price target.